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Abstract 
The molecular characterization of various cancers has shown that cancers with the same origins, histopathologic 
diagnoses, and clinical stages can be highly heterogeneous in their genetic and epigenetic alterations that cause 
tumorigenesis. A number of cancer driver genes with functional abnormalities that trigger malignant transforma-
tion and that are required for the survival of cancer cells have been identified. Therapeutic agents targeting some of 
these cancer drivers have been successfully developed, resulting in substantial improvements in clinical symptom 
amelioration and outcomes in a subset of cancer patients. However, because such therapeutic drugs often benefit 
only a limited number of patients, the successes of clinical development and applications rely on the ability to identify 
those patients who are sensitive to the targeted therapies. Thus, biomarkers that can predict treatment responses 
are critical for the success of precision therapy for cancer patients and of anticancer drug development. This review 
discusses the molecular heterogeneity of lung cancer pathogenesis; predictive biomarkers for precision medicine in 
lung cancer therapy with drugs targeting epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), 
c-ros oncogene 1 receptor tyrosine kinase (ROS1), and immune checkpoints; biomarkers associated with resistance to 
these therapeutics; and approaches to identify predictive biomarkers in anticancer drug development. The identifica-
tion of predictive biomarkers during anticancer drug development is expected to greatly facilitate such development 
because it will increase the chance of success or reduce the attrition rate. Additionally, such identification will accel-
erate the drug approval process by providing effective patient stratification strategies in clinical trials to reduce the 
sample size required to demonstrate clinical benefits.
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Background
A recent study analyzing the global disease burden 
revealed that lung cancer is the second leading cause of 
death in the United States and in most other high-income 
countries [1]. In China, lung cancer is the fifth leading 
cause of death, following stroke, ischemic heart disease, 
road injuries, and chronic obstructive pulmonary dis-
ease [1, 2]. Globally, the annual incidence of lung cancer 
is approximately 1.8 million, with an annual mortality of 
approximately 1.6 million [3, 4]. The 5-year overall sur-
vival (OS) rate for lung cancer patients in the United 
States has improved only moderately over the past four 
decades from 12.2% in 1975 to 17.8% in 2010, despite the 
use of many therapeutic modalities [5–7]. The 5-year OS 
rate of lung cancer patients in China is approximately 
16.1% [8], which is close to that observed in the United 
States. Histologically, lung cancer is classified as small cell 
lung cancer (SCLC, approximately 15%) and non-small 
cell lung cancer (NSCLC, approximately 85%); the latter 
includes adenocarcinoma, squamous cell carcinoma, and 
large cell carcinoma. Tobacco smoking is the major cause 
for all types of lung cancer, particularly SCLC and squa-
mous cell carcinoma [9]. Air pollution is another major 
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cause of lung cancer, as a substantial number of lung can-
cer deaths in China and other East Asian countries may 
be attributed to fine particles in the air [10–12].
Small cell lung cancer is highly aggressive, and most 
(95%) SCLC patients are current or former smokers [13, 
14]. Although the initial response rate to platinum-based 
chemotherapy and radiotherapy is high, recurrence and 
resistance occur inevitably in most SCLC patients, leading 
to 5-year OS rates of approximately 24% for patients with 
limited-stage SCLC and of less than 3% for those with 
metastases [5]. Fortunately, the incidence of SCLC in the 
United States has been declining over the past decades 
because of a decreasing prevalence of tobacco smoking 
[15]. For NSCLC, surgical resection is the standard care 
for patients with stage I disease, whereas surgical resec-
tion plus adjuvant therapy is used for patients with stages 
II–III disease. NSCLC patients at the advanced stages 
(stages IIIB–IV) are usually treated with chemotherapy, 
pathway-targeted therapies, and/or supportive medicine. 
Early diagnosis is the major factor proven to improve out-
comes [16]; the 5-year OS rate is approximately 70% for 
patients with stage I NSCLC and drops to approximately 
5% for patients with stage IV lung cancer [17]. Unfortu-
nately, most lung cancers are diagnosed at an advanced 
stage and thus have a poor prognosis [9]. Early detec-
tion by low-dose computed tomography (CT) screening 
significantly reduces lung cancer mortality; nevertheless, 
approximately 96% of the positive results detected by such 
screening are false positives [18]. Moreover, the current 
estimated cost of screening to avoid one premature lung 
cancer death is approximately $240,000, thereby adding 
substantial expenditures to the health care system [19].
Advances in molecular profiling and targeted therapy 
have shown that subgroups of lung cancer patients are 
highly sensitive to some small-molecule inhibitors tar-
geting key molecular nodes that drive carcinogenesis in 
those patients, such as epidermal growth factor receptor 
(EGFR) and anaplastic lymphoma kinase (ALK). These 
breakthrough discoveries have not only led to a new par-
adigm of biomarker-directed precision or personalized 
therapy but also greatly accelerated the development of 
novel anticancer drugs. It is now clear that mutations in 
cancer driver genes and alterations in gene expression 
and/or posttranscriptional modifications can all dras-
tically affect treatment responses or clinical outcomes 
[20–22]. Moreover, the success of targeted anticancer 
therapy largely depends on biomarkers that can identify 
patient subgroups that may respond to specific thera-
peutic agents because alterations in a particular cancer 
driver usually exist in only a small subset of patients. 
This review discusses recent advances in predictive bio-
marker-directed precision medicine and drug develop-
ment for lung cancers.
Molecular heterogeneity in lung cancer
Genome-wide gene sequencing analyses have found 
that each lung cancer may have an average of approxi-
mately 150 somatic mutations that are expected to alter 
their protein products; this number is much higher than 
the average of 30–60 mutations observed in other solid 
tumors [23]. The high somatic mutation rates observed in 
lung cancer reflect the mutagenic roles of cigarette smok-
ing in the pathogenesis of lung cancer. Indeed, the total 
number of point mutations in coding regions identified in 
lung cancer is approximately 10 times higher in smokers 
than in non-smokers [24]. Smoking also causes distinct 
changes in gene mutation and gene expression signatures 
in cancer tissues and normal lung tissues [25, 26]. Smok-
ing-induced gene expression alterations observed in nor-
mal lung tissues can be transient because the majority of 
changes at the expression level can revert to non-smoker 
levels following smoking cessation [26]. Nevertheless, 
some of these expression changes are irreversible and 
permanent [26].
The results from genome-wide sequencing analyses 
for primary lung adenocarcinoma [24, 25, 27, 28], squa-
mous cell cancer [29], SCLC [30, 31], and carcinoids or 
neuroendocrine tumors [32] have been reported recently 
by several groups. Information regarding genetic altera-
tions (mutations and copy number changes), mRNA 
expression data, and protein/protein phosphorylation 
levels in lung adenocarcinoma, squamous cell cancer, 
and SCLC can be retrieved from The Cancer Genome 
Atlas (TCGA) databases and publically available data-
sets at the website http://www.cbioportal.org. Figure  1 
shows the frequencies of cancer driver genes that are 
frequently mutated (including copy number changes) in 
lung adenocarcinoma, squamous cell cancer, and SCLC. 
Based on data retrieved from cBioPortal, tumor protein 
p53 (TP53) is the most frequently mutated cancer driver 
gene for all three histological types of lung cancer, with 
frequencies varying from 46% in adenocarcinoma to 86% 
in SCLC. Additionally, Kirsten rat sarcoma viral onco-
gene homolog (KRAS), cyclin-dependent kinase inhibi-
tor 2A (CDKN2A), mixed-lineage leukemia 3 (MLL3), 
serine/threonine kinase 11 (STK11), kelch-like ECH-
associated protein 1 (KEAP1), and EGFR are the top 
frequently mutated genes detected in lung adenocarci-
nomas. Phosphatidylinositol-4,5-biphosphate 3-kinase, 
catalytic subunit alpha (PIK3CA), sex-determining 
region Y-related gene family 2 (SOX2), CDKN2A, TP63, 
fibroblast growth factor receptor 1(FGFR1), and MLL2 
are the top mutant genes in squamous cell cancer; ret-
inoblastoma 1 (RB1), E1A-binding protein p300 (EP300), 
MLL2, smoothened (SMO), and PIK3CA are the top 
mutant genes in SCLC. Our recent sequencing analysis 
of the exomes of 200 cancer-related genes found that 
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mutations in TP53, KRAS, MLL3, SET domain-contain-
ing 2 (SETD2), AT rich interactive domain 1A (ARID1A), 
PIK3CA, and ALK were frequently detected in primary 
tumors and corresponding patient-derived xenografts 
of NSCLC [33]. Most of the mutations (93%) detected 
in the primary tumors were also detected in their 
corresponding patient-derived xenografts. Neverthe-
less, the numbers of mutations detected in each primary 
tumor varied greatly, and most tumors had mutations in 
more than two genes. The results from these molecular 
profiling studies clearly demonstrated heterogeneity in 






































































































































































































































































































































































































Figure 1 Frequencies of genetic alternations (mutations and copy number changes) in cancer driver genes. The frequencies for the top 30 
mutated genes in lung adenocarcinoma, squamous cell carcinoma, and small cell lung cancer were retrieved from http://www.cbioportal.org. TP53 
tumor protein p53; KRAS Kirsten rat sarcoma viral oncogene homolog; CDKN2A cyclin-dependent kinase inhibitor 2A; MLL3 mixed-lineage leukemia 
3; STK11 serine/threonine kinase 11; KEAP1 kelch-like ECH-associated protein 1; EGFR epidermal growth factor receptor; RIT1 Ras-like without CAAX 
1; NKX2-1 NK2 homeobox 1; SETBP1 SET-binding protein 1; ATM ataxia telangiectasia-mutated; CARD11 caspase recruitment domain family, member 
11; MET MET proto-oncogene; NF1 neurofibromin1; SKP2 S-phase kinase-associated protein 2; BRAF v-Raf murine sarcoma viral oncogene homolog 
B1; GNAS GNAS complex locus; MYC v-myc avian myelocytomatosis viral oncogene homolog; MGA MAX dimerization protein; CDC73 cell division 
cycle 73; PIK3CA phosphatidylinositol-4,5-biphosphate 3-kinase, catalytic subunit alpha; SETD2 SET domain-containing 2; MDM2 mouse double 
minute 2 homolog; RBM10 RNA-binding motif protein 10; ERBB4 erb-b2 receptor tyrosine kinase 4; ALK anaplastic lymphoma kinase; ARID1A AT rich 
interactive domain 1A; SOX2 sex-determining region Y-related gene family 2; FGFR1 fibroblast growth factor receptor 1; NFE2L2 nuclear factor, eryth-
roid 2-like 2; CCND1 cyclin D1; PTEN phosphatase and tensin homolog; FOXL2 forkhead box L2; NOTCH2 notch 2; PDGFRA platelet-derived growth 
factor receptor, alpha polypeptide; KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; CREBBP CREB-binding protein; PAX5 paired 
box 5; SLIT2 slit homolog 2; JAK2 Janus kinase 2; RB1 retinoblastoma 1; SMARCA4 SWI/SNF-related, matrix-associated, actin-dependent regulator of 
chromatin, subfamily a, member 4; EP300 E1A-binding protein p300; SMO smoothened; EPHA7 EPH receptor A7; MED12 mediator complex subunit 
12; KDM6A lysine (K)-specific demethylase 6A; FAM123B family with sequence similarity 123B; B2M beta-2-microglobulin; CYLD cyclin dromatosis 
(turban tumor syndrome); GATA2 GATA-binding protein 2; BRCA1 breast cancer early onset.
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in Figure 2a, the mutational status of the top seven fre-
quently mutated cancer driver genes varied greatly in 
230 lung adenocarcinomas [28]. Moreover, mutations 
in those genes, particularly for tumor suppressor genes 
such as TP53 (Figure 2b), are often widely distributed in 
the entire coding region. Evidence has shown that muta-
tions in TP53 can lead to either loss or gain of functions 
[34–38], and both may promote tumorigenesis through 
different mechanisms. Similarly, different mutations in 
KRAS, even if in the same codon such as G12C, G12V, 
and G12D mutations in the KRAS gene, may lead to dif-
ferent conformational changes in KRAS and have differ-
ent effects on clinical outcomes and molecular pathway 
activation [39]. Ultimately, this molecular heterogeneity 
may affect treatment responses to therapeutics targeting 
different pathways.
Notably, however, current TCGA data are derived 
mostly from patients in Western countries. The muta-
tional status in other ethnic populations may differ 
[40–42]. For example, activated EGFR mutations are 
detected in approximately 10–17% of lung adenocar-
cinoma patients in the United States and Europe [27, 
43–46] but in approximately 30–65% of lung adenocarci-
noma patients in Asia [47–50]. In contrast, KRAS muta-
tions were detected in 35–50% of lung adenocarcinomas 
in Caucasian patients [28, 51] but in less than 5% of lung 
Figure 2 Molecular heterogeneity in lung adenocarcinoma. a The status of genetic alterations in 230 lung adenocarcinomas retrieved from The 
Cancer Genome Atlas (TCGA) database [28]. The mutation frequencies (%) are shown on the left of graph. Each vertical line represents a tumor. 
The graph shows mutations in the top seven cancer driver genes in lung adenocarcinoma. Red amplification, blue homozygous deletion, green 
missense mutation, black truncating mutation, brown in-frame mutation. b, c Mutations in EGFR and TP53 in the same 230 adenocarcinomas. The 
gray bars represent the entire lengths of the EGFR and TP53 proteins, with the number of amino acids indicated at the bottom of each gray bar. The 
green, red, and blue boxes indicate protein domains. The lines and dots indicate the locations and frequencies of mutations detected in the EGFR and 
TP53 genes. Green missense mutations, red nonsense or frameshift mutations, black in-frame deletions. The data were retrieved from http://www.
cbioportal.org.
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adenocarcinomas in Chinese patients [48, 49, 52]. Never-
theless, changes in molecular signaling can occur in the 
absence of gene mutations. Indeed, the activation of RAS 
signaling pathways can be detected in substantial num-
bers of primary tumors with wild-type RAS genes [53]. 
Increased expression of the RAS genes [54, 55], increased 
upstream signaling from tyrosine kinase growth factor 
receptors such as v-erbB2 avian erythroblastic leukemia 
viral oncogene homolog 2 (HER2) and EGFR [56, 57], 
and altered expression of microRNAs such as let-7 [58, 
59] may all contributes to the activation of RAS signaling 
pathways.
Biomarker‑directed precision medicine for lung 
cancer
Anti‑EGFR therapy
Epidermal growth factor receptor, a major driver in lung 
tumorigenesis, has been extensively investigated as a 
target for anticancer therapy. As noted above, activating 
EGFR mutations are detected in substantial numbers of 
lung cancer patients and are more commonly observed 
in women and non-smokers [27, 43–46]. The finding that 
EGFR mutations in primary lung cancer are associated 
with sensitivity to EGFR inhibitors gefitinib and erlo-
tinib [44, 60, 61] contributed greatly to the final approval 
of these therapeutics for the treatment of lung cancer. 
Subsequently, EGFR gene mutations have served as bio-
markers in the clinic for the identification of responders 
to EGFR inhibitors. Both gefitinib and erlotinib (Figure 3) 
are the first choice for therapy in lung cancer patients 
whose tumors harbor EGFR mutations and are reported 
to significantly prolong progression-free survival (PFS) 
in patients with EGFR-mutant lung cancer [62–64]. Ico-
tinib, which has a clinical efficacy similar to that of gefi-
tinib but less adverse effects [65], is approved for the 
treatment of EGFR-mutant lung cancer in China.
As shown in Figure 2, mutations in EGFR are also het-
erogeneous. There are multiple locations in the EGFR 
gene where driver mutations can occur, and these muta-
tions associate with differential sensitivity to EGFR inhi-
bition. The most common EGFR mutations are in-frame 
deletions in exon 19 and L858R point mutations in exon 
21. Together, these mutations account for approximately 
85% of the EGFR mutations observed in lung cancer [46, 
48, 66]; tumors with these mutations are highly sensitive 
to treatment with erlotinib, gefitinib, and the second-gen-
eration EGFR inhibitor afatinib [63, 67–69]. Tumors with 
other less common mutations, such as exon 18 mutations 
at G719 and exon 21 mutation L861Q, are also suscep-
tible to treatment with EGFR inhibitors [60, 70]. Never-
theless, tumors with exon 20 in-frame insertions, which 
account for approximately 4–10% of all EGFR mutations, 
usually do not respond to treatment with EGFR inhibi-
tors [71–73]. Although these insertional mutations acti-
vate EGFR, they do not have increased affinity for EGFR 
inhibitors, as is observed for other EGFR mutations [74].
However, despite initial dramatic responses to gefitinib 
and erlotinib in patients with EGFR-mutant lung can-
cers, acquired resistance inevitably occurs at a median 
of 10–13 months after treatment initiation [69, 75, 76]. A 
number of mechanisms for this acquired resistance have 
been identified, including a secondary T790M muta-
tion at exon 20 of the EGFR gene [77–79], amplification 
of the MET proto-oncogene (MET) [80–82] or HER2 


































































Figure 3 Chemical structures of anti-EGFR therapeutic agents.
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gene [83, 84], mutations of the KRAS gene [85], activa-
tion of AXL receptor tyrosine kinase (AXL), V-Srcavian 
sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog 
(SRC) kinases [86–88], and extracellular signal-regu-
lated kinase (ERK) [89], loss of phosphatase and ten-
sin homolog (PTEN) [90], and activation of the nuclear 
factor-κB (NF-κB) [91] or interleukin-6 receptor (IL-
6R)/signal transducer and activator of transcription 3 
(STAT3) pathway [92, 93]. Among these mechanisms, the 
most common cause of resistance observed clinically is 
acquisition of the EGFRT790M mutation, which is found 
in approximately 50% of patients [77, 80, 94]. A number 
of second-generation EGFR inhibitors, most of which are 
irreversible, inhibit two or more receptors in the EGFR 
family, and may have some activity in T790M-mutant 
cancers, have been evaluated in clinical trials [95–98]. 
Among those evaluated in clinical trials, only afatinib [96, 
99] has been approved (in July 2013) by the United States 
Food and Drug Administration (FDA) for the treatment 
of metastatic NSCLC with EGFR mutations. Unfortu-
nately, diarrhea and rash, the two most common adverse 
effects associated with a good response to the therapy, 
appear to be more severe in patients treated with afatinib 
than those treated with erlotinib or gefitinib [100]. More 
recently, the third-generation EGFR inhibitors AZD9291 
[101] and CO-1686 [102, 103] have shown promising 
anticancer activity in T790M-mutant tumors. Our recent 
studies have revealed that ibrutinib, an irreversible inhib-
itor of Bruton tyrosine kinase (BTK) that was recently 
approved by the FDA for the treatment of mantle cell 
lymphoma and chronic lymphocytic leukemia [104, 105], 
can function as an EGFR inhibitor to selectively inhibit 
growth and induce apoptosis in EGFR-mutant NSCLC 
cells in vitro and in vivo, including erlotinib-resistant 
cells that harbor a T790M mutation [106]. Because ibru-
tinib was recently reported to be well tolerated when 
used in combination with other targeted therapeu-
tics [107, 108], it may have advantages in combination 
therapy to overcome resistance caused by alternative or 
bypass survival signals from cooperative or parallel path-
ways, as is observed in T790M-negative resistant cells.
Anti‑ALK/ROS1 therapy
The discovery of gene rearrangements between the echi-
noderm microtubule-associated protein-like 4 (EML4) 
gene and the ALK gene that lead to constitutive activa-
tion of ALK in NSCLC [109, 110] greatly contributed to 
the subsequent development and approval of crizotinib, 
a small-molecule inhibitor of ALK, c-ros oncogene 1 
receptor tyrosine kinase (ROS1), and MET. EML4/ALK 
rearrangements are detected in approximately 4–5% 
of patients with NSCLC, mostly in young patients with 
adenocarcinoma who are non-smokers or light smokers 
[111–114]. ALK rearrangements were found to be mutu-
ally exclusive with EGFR and KRAS mutations, although 
they share common downstream signaling pathways with 
EGFR such as the RAS/RAF/MEK/ERK, PI3K/AKT/
mTOR, and JAK/STAT pathways. Crizotinib (Figure  4) 
was originally developed as an MET inhibitor; however, 
crizotinib also inhibits ALK and ROS1 [115]. Soon after 
the first reports of EML4/ALK rearrangement and its 
role in lung cancer oncogenesis [109, 110], a diagnostic 
method for detecting EML4/ALK rearrangement by fluo-
rescence in situ hybridization (FISH) was developed, and 
patients with EML4/ALK rearrangement-positive lung 
cancer were enrolled in clinical trials with crizotinib [114, 
116]. Most of the patients with advanced ALK-positive 
NSCLC responded to crizotinib treatment, resulting in 
tumor shrinkage or disease stabilization. The objective 
response rate was approximately 60%, and the median 
PFS was 8–10  months [117, 118]. In comparison, con-
ventional chemotherapy for the same type of patients 
achieved a response rate of approximately 20% and a PFS 
of 2–3  months [117, 118]. Subsequently, crizotinib was 
approved for the treatment of ALK-positive NSCLC in 
conjunction with an FDA-approved diagnostic assay, the 
Vysis ALK BreakApart FISH Probe Kit.
ROS1 gene rearrangement and activation are detected 
in approximately 1–1.5% of NSCLC, predominantly in 
adenocarcinoma and in non-smokers, as is observed 
with ALK rearrangement [119–121]. However, ROS1 and 
ALK rearrangements rarely occur in the same tumors. 
Because the kinase domains of ALK and ROS1 share 77% 
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Figure 4 Chemical structures of anti-ALK/ROS1 therapeutic agents. ROS1 c-ros oncogene 1 receptor tyrosine kinase.
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homology at the protein sequence level and crizotinib 
is highly active for both ALK and ROS1 [115], clinical 
investigation into the treatment of NSCLC patients with 
ROS1 rearrangement has been pursued. The results indi-
cated that crizotinib also has marked antitumor activ-
ity in patients with ROS1-rearranged advanced NSCLC, 
with an objective response rate of 72% and a median 
response duration of approximately 17.6  months [122]. 
The response duration in ROS1 rearrangement-positive 
patients appears to be longer than that in ALK-positive 
patients (10–11  months). Similar to the diagnosis of 
ALK rearrangement, FISH and/or reverse transcription-
polymerase chain reaction (RT-PCR) are used to identify 
patients with ROS1 rearrangement [122]. Nevertheless, 
resistance to crizotinib eventually occurs in both ALK- 
and ROS1-positive patients.
Among the patients with ALK-positive NSCLC who 
acquired resistance to crizotinib, one-third had various 
secondary mutations in the ALK kinase domain and/or 
had ALK gene amplification [111]. Resistance can also 
be caused by aberrant activation of alternative or bypass 
pathways, such as marked v-kit Hardy-Zuckerman 4 
feline sarcoma viral oncogene homolog (KIT) amplifica-
tion and EGFR activation [123]. In some patients, mul-
tiple resistance mechanisms may exist simultaneously, 
indicating that combination therapy will be required 
to overcome resistance [124, 125]. Second-generation 
ALK inhibitors have been developed to overcome crizo-
tinib resistance caused by mutations in the ALK kinase 
domain. Among these ALK inhibitors, ceritinib has 
been approved by the FDA for the treatment of ALK-
positive NSCLC in the United States, and alectinib has 
been approved in Japan [126, 127] (Figure  4). Ceritinib 
is reported to be effective in patients with various resist-
ant mutations. Of the patients who had received crizo-
tinib previously, 56% responded to ceritinib treatment, 
including patients with central nervous system metas-
tases [126, 128]. Nevertheless, ceritinib resistance has 
been observed in the clinic. Resistant cells obtained from 
patients treated with ceritinib revealed activation of the 
EGFR, mitogen-activated protein (MAP) kinase, and SRC 
pathways, and the cells were sensitive to combination 
therapies with inhibitors for EGFR, MAP kinase-ERK 
kinase (MEK), and SRC [129]. MET activation has been 
reported to cause resistance to alectinib because, as an 
ALK selective inhibitor, alectinib does not inhibit MET 
[130].
Immunotherapy
The presence of tumor antigens derived from mutant 
proteins, dysregulated or overexpressed proteins, and 
viral oncogenic proteins has inspired intensive investi-
gation into anticancer immunotherapy through various 
approaches [131]. The high mutation rates observed in 
lung cancers suggest that lung cancer cells may possess 
high levels of tumor antigens from mutant proteins and 
may therefore be vulnerable to immunotherapy. How-
ever, during malignant evolution, cancer cells obtain 
the ability to escape immune system recognition and 
destruction through various mechanisms, including 
inhibiting tumor antigen presentation by the down-regu-
lation of class I major histocompatibility complex (MHC) 
molecule expression on the surface of tumor cells, 
recruiting immunosuppressive cells (such as regulatory T 
cells, myeloid-derived suppressor cells, and tumor-asso-
ciated macrophages) to the tumor microenvironment, 
secreting immunosuppressive cytokines [such as IL-10 
and tumor growth factor-β (TGF-β)], activating immune 
co-inhibitory checkpoint receptors [such as cytotoxic T 
lymphocyte-associated antigen-4 (CTLA-4) and pro-
grammed death-1 (PD-1)], and inhibiting immune co-
stimulatory receptors (CD40, OX40, CD137, and CD28) 
[132–134]. Advances in the mechanistic characterization 
of tumor cell evasion of immunosurveillance have led to 
the development of various approaches that aim to mobi-
lize the immune system for the elimination of malignant 
cells. Currently, the most advanced available therapeutics 
developed for lung cancer are monoclonal antibodies that 
target checkpoints of the immune regulation cascade.
Immune checkpoints regulate the amplitude and dura-
tion of immune responses, preventing damage to normal 
tissues from overactivation of the immune system [132–
134]. The key players in the checkpoints include CTLA-
4, lymphocyte activation gene-3 (LAG-3), and PD-1, 
as well as the PD-1 ligands PD-L1 and PD-L2. CTLA-4 
is constitutively expressed in regulatory T cells but only 
transiently expressed in activated cytotoxic T cells. It 
shares common ligands, CD80 and CD86, with the co-
stimulatory receptor CD28. The interaction of CD28 with 
these ligands leads to the full activation of cytotoxic T 
cells, whereas the interaction of CTLA-4 with the ligands 
prevents T cell activation. The up-regulation of CTLA-4 
was detected in anergic lymphocytes, and the block-
ade of CTLA-4 with anti-CTLA-4 antibodies resulted 
in antitumor activity [135]. The anti-CTLA-4 antibody 
ipilimumab is approved for the treatment of melanoma 
[136] and is currently in clinical trials for the treatment 
of NSCLC. PD-1 (also known as PDCD1 or CD279) is 
expressed in T, B, and natural killer (NK) cells. The inter-
action of PD-1 with its ligands, PD-L1 (also called B7-H1 
or CD274) and PD-L2 (B7-DC), suppresses T cell activa-
tion and promotes T cell apoptosis [137–139], leading to 
immune evasion. The expression of PD-L1 in lung can-
cer is detected in 25–50% of NSCLC cases, depending 
on the assays used to detect its protein or mRNA [140], 
and is associated with the presence of EGFR mutations 
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in NSCLC [141]. EGFR activation induced PD-L1 expres-
sion in bronchial epithelial cells, whereas treatment with 
EGFR inhibitors reduced PD-L1 expression [142]. PD-1 
monoclonal antibodies (nivolumab and pembrolizumab) 
have been approved for the treatment of melanoma 
[143–146]. The objective response rates in melanoma 
patients are approximately 26–40% [143, 144, 146]. 
Nivolumab was approved for the treatment of NSCLC in 
the United States in March 2015 [147] and was found to 
be highly active in treating Hodgkin’s lymphoma [148]. 
Monoclonal antibodies for PD-L1 are also under inten-
sive clinical evaluation for the treatment of NSCLC and 
other solid tumors [149, 150]. The objective response 
rates in patients with advanced NSCLC are approxi-
mately 17–20% in patients receiving ≥1  mg/kg of anti-
PD1 or anti-PD-L1 antibodies every 2–3 weeks, and the 
responses may last 1 year or longer [147, 149–151]. The 
response rates to both anti-PD1 and anti-PD-L1 antibod-
ies were significantly higher in PD-L1-positive patients 
than in PD-L1-negative patients [150, 151]. In a trial 
with an anti-PD1 antibody, 9 (36%) of 25 PD-L1-positive 
patients responded to the treatment, whereas none of 
17 PD-L1-negative patients had an objective response 
[151]. The study with the anti-PD-L1 antibody also 
found that responses were often observed in patients 
with tumors expressing high levels of PD-L1, especially 
if PD-L1 was expressed by tumor-infiltrating immune 
cells. The expression of CTLA-4, the absence of frac-
talkine (CX3CL1) [150], and the presence of pre-existing 
CD8+ T cells distinctly located at the invasive tumor 
margin [145] were also found to be associated with treat-
ment responses to the PD1/PD-L1 blockage antibodies. 
These results demonstrated the feasibility of using the 
expression of PD-L1 and the presence of immune cells 
in tumor sites for patient stratification for PD1/PD-L1 
blockade therapy. Nevertheless, larger clinical trials will 
be required to further validate the associations between 
PD-L1 expression and improved clinical outcomes.
Predictive biomarkers in anticancer drug 
development
Anticancer drug development has a high failure or attri-
tion rate, primarily because of a lack of efficacy, inability 
to identify responders, and intolerable toxic effects [152, 
153]. Only approximately 5% of anticancer agents evalu-
ated in human studies between 1991 and 2000 were suc-
cessfully approved for clinical applications [152, 154]. 
The majority (80%) of phase III failures were caused by 
a lack of efficacy [152, 154–156] that resulted from a 
lack of efficacy proof-of-concept in humans and a lack 
of objective biomarkers capable of reporting such effi-
cacy [152, 154]. The development of the anti-EGFR drugs 
gefitinib and erlotinib and the anti-ALK/ROS1 drugs 
crizotinib and ceritinib has provided excellent examples 
of using predictive biomarkers and patient stratifications 
in clinical trials to increase the chance of success or to 
reduce the attrition rate in anticancer drug development. 
Notably, both gefitinib [64, 157, 158] and erlotinib [159, 
160] failed to show a benefit in randomized phase III tri-
als with unselected patient populations. Similarly, the 
successes of the v-Raf murine sarcoma viral oncogene 
homolog B1 (BRAF) inhibitor vemurafenib [161, 162] 
and the poly(ADP-ribose) polymerase (PARP) inhibi-
tor olaparib [163–165] in anticancer therapy relied on 
biomarker-based patient stratifications in clinical tri-
als. In fact, the inability to identify cancers that are most 
likely to respond to a treatment is a major challenge in 
anticancer drug development, not only leading to failure 
to demonstrate the potential benefit of a promising anti-
cancer agent [64, 166] but also exposing patients to the 
risks of ineffective treatments. Indeed, a lack of predic-
tive biomarkers for patient stratification has halted fur-
ther development of many other investigational drugs 
[167–170]. Thus, reliable predictive biomarkers are cru-
cial to the success of anticancer drug development, and 
the simultaneous development of predictive biomarkers 
will be highly desirable for promising anticancer drug 
candidates.
The identification of predictive biomarkers can be 
relatively straightforward if the therapeutic targets are 
themselves the cancer drivers and if the cancer cells are 
addicted to the presence of those targets for survival. As 
in the cases of EGFR, ALK, and ROS1, the constitutive 
activation of such targets is the driving cause of a subset 
of NSCLC and is required for the survival of those can-
cer cells; therefore, the presence of constitutive activating 
mutations or gene rearrangement can be explored as pre-
dictive biomarkers for patient stratification. Nevertheless, 
cancer cells can be killed indirectly through synthetic 
lethality between the cancer drivers and their synthetic 
lethal partners, as has been demonstrated using the 
PARP inhibitor olaparib to eliminate breast cancer early 
onset (BRCA)-mutant ovarian and breast cancer cells 
[165, 171, 172]. In this case, loss-of-function mutations 
in the BRCA1 and BRCA2 genes or other functional defi-
ciencies in the DNA repair pathways will serve as predic-
tive biomarkers for response to olaparib and other PARP 
inhibitors [173]. Synthetic lethality is a lethal phenotype 
caused by the combined effects of mutations in two or 
more genes. This concept has recently been exploited 
for the development of novel genotype-selective antican-
cer agents and/or the identification of novel therapeu-
tic targets [173–176]. This approach could be useful for 
the indirect targeting of cancer drivers such as genetic 
changes in TP53, STK11, RB1, and RAS genes that are 
nondruggable or difficult to target using small molecules. 
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Notably, a study conducting short hairpin RNA (shRNA) 
library screening for genes that may have synthetic lethal 
interactions in the oncogenic KRAS gene in the colon 
cancer cell line DLD-1 and its isogenic derivatives led 
to the identification of approximately 370–1,600 KRAS 
synthetic lethal genes, depending on the stringencies of 
statistical analyses [177], demonstrating the diversity 
of biological processes or pathways regulated by KRAS. 
The molecular pathology of RAS-mediated oncogenesis 
is further complicated by the fact that cancer cells with 
different mutations in KRAS, even if in the same codon 
(such as G12C, G12V, and G12D mutations), may lead to 
different conformational changes in KRAS, have different 
effects on clinical outcomes, and activate different molec-
ular and metabolic pathways [39, 178]. Moreover, a sub-
stantial number of KRAS-mutant tumors have mutations 
in other cancer driver genes such as TP53, CDKN2A, and 
STK11. Studies in transgenic mice have found that acti-
vating mutations in KRAS predispose mice to early-onset 
lung adenocarcinoma [179, 180]. Nevertheless, such 
tumors do not have an invasive or metastatic phenotype 
[181]. Metastasis will occur only when additional genetic 
changes, such as Tp53 mutations or Stk11 deletion, are 
introduced [182, 183]. Finally, the RAS activation signa-
ture is observed in approximately 25% of KRAS wild-type 
cancers [53] because increased RAS activity in human 
cancers can result from RAS gene amplification [184, 
185] or overexpression [55], an increase in upstream sig-
nals from tyrosine kinase growth factor receptors such as 
HER2 and EGFR [56, 57], or a decrease in the expression 
of microRNAs such as let-7 family members [58].
The above-discussed situations impose considerable 
challenges on the identification of predictive biomarkers 
for anti-RAS therapeutics developed through synthetic 
lethality screening. Substantial efforts will be required 
to identify predictive biomarkers for such therapeu-
tic agents. Through synthetic lethality screening using 
a chemical library for isogenic cell lines with and with-
out oncogenic KRAS, we previously reported a small 
molecule, designated oncrasin-1, that induces apopto-
sis in several KRAS-mutant lung cancer cell lines [186]. 
The in vitro and in vivo activities were optimized by the 
synthesis and evaluation of analogues [187–190]. The 
mechanistic characterization revealed that these com-
pounds induce oxidative stress, activate c-Jun N-terminal 
kinase (JNK), and inhibit RNA polymerase II, STAT3, 
and cyclin D1 [187, 188, 191–194]. However, a predic-
tive biomarker for oncrasin compounds remained elusive 
until our recent discovery that such compounds require 
the expression of a sulfotransferase (SULT), SULT1A1, 
in cancer cells for their anticancer activity and that the 
expression of SULT1A1 is capable of predicting the 
responses to oncrasin compounds [195]. SULT1A1 is a 
biotransformation enzyme that bioactivates several pro-
carcinogens [196–202] and some anticancer drugs such 
as tamoxifen [203]. The identification of SULT1A1 as a 
predictive biomarker for oncrasin compounds shed light 
on mechanisms of the selectivity and, possibly, the toxic-
ity of these compounds [204]. The process of identifying 
this predictive biomarker underscores the importance 
of activity characterization in a large set of molecularly 
annotated cancer cell lines and of collaborations between 
biostatisticians and molecular biologists. Statistical anal-
ysis of associations between the activity of NSC-743380 
(oncrasin-72) and the gene expression profile in the NCI-
60 cell line panel led to the identification of a number of 
candidate genes, and subsequent molecular characteriza-
tions demonstrated the causal relationship between the 
expression of SULT1A1 and the anticancer activity of 
NSC-743380, validating the feasibility of using SULT1A1 
as a predictive marker for those compounds [195]. Larger 
panels of molecularly annotated cancer cell lines have 
also been used by other groups for the identification of 
predictive biomarkers for larger sets of anticancer drugs 
[150, 205–209]. Ultimately, rigorous validation of causal 
relationships between the sensitivity and the biomarker 
will be essential for successful clinical translations.
Conclusion
The diversity found in the molecular pathogenesis of lung 
cancer demonstrates that conventional histology-based 
classifications of the disease are not sufficient to provide 
guidance for treatment decisions in the clinic. Classifi-
cations based on molecular pathology are required for 
precision therapy. The successful development of anti-
EGFR and anti-ALK/ROS1 therapeutics has proven the 
critical role of predictive biomarkers in anticancer drug 
development because the ability to identify patient sub-
populations who may benefit from a drug candidate will 
directly affect the design and patient selection of clini-
cal trials, dramatically reduce the sample size required 
to reveal potential benefits, and increase the chance of 
success. It is expected that more efforts will be devoted 
to the identification of predictive biomarkers and the 
development of effective assays for biomarkers during 
drug development. These efforts will likely be rewarded 
by increased success rates when the drug candidates 
enter clinical trials. Advances in technologies, such as 
next-generation sequencing and digital polymerase chain 
reaction, will also facilitate the detection of changes in 
genotypes and/or in DNA or RNA levels and the devel-
opment of effective assays for biomarkers. On the other 
hand, biomarker-directed patient stratification has 
changed the clinical practice of anticancer therapy and 
has substantially improved treatment efficacy by provid-
ing guidance for the selection of optimal treatment for 
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some lung cancer patients. However, biomarker-directed 
personalized therapy can currently benefit only a limited 
number of patients because most of the currently avail-
able predictive biomarkers occur infrequently [24, 27, 
210] and because response-predictive biomarkers are not 
available for most first-line anticancer therapeutics. Thus, 
alternative approaches will be required to identify the 
appropriate therapeutics for a particular patient. Such 
patient-oriented approaches may require direct testing 
of the drug sensitivity of a patient’s cancer cells to vari-
ous available anticancer therapeutics rather than predict-
ing drug sensitivity based on the presence or absence of 
predictive biomarkers. Some recent studies have shown 
the feasibility of testing for the treatment responses of 
patient-derived tumor xenografts [211, 212] and/or pri-
mary cell cultures [213] to identify effective treatment 
regimens. Nevertheless, technology improvements and 
rigorous validations are required before such techniques 
can be used commonly in clinical practice.
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